Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension

Clinical Ophthalmology

Volumn 8, Issue , 2014, Pages 219-228

  Nagayama, Mikio ^a   Nakajima, Toru ^b   Ono, Junji ^c  

^a Nagayama Eye Clinic   (Japan)

^b Nakajima Eye Clinic   (Japan)

^c Ono Ophthalmic Clinic   (Japan)

Author keywords

Azarga ; Intraocular pressure; Open angle glaucoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BRINZOLAMIDE; BRINZOLAMIDE PLUS TIMOLOL; TIMOLOL;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC CONJUNCTIVITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CONTROLLED STUDY; CORONARY SPASTIC ANGINA; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EYE DISCHARGE; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; ISCHEMIC HEART DISEASE; JAPANESE; KERATITIS; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE OBSTRUCTION; OCULAR HYPEREMIA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PHASE 2 CLINICAL TRIAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING;

EID: 84892603963     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S55590     Document Type: Article

References (37)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.
2. Yamada M, Hiratsuka Y, Roberts CB, et al. Prevalence of visual impairment in the adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol. 2010;17(1):50-57.
3. Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs Aging. 2008;25(9):729-759.
4. Gestel AV, Webers CA, Beckers HJ, Peeters A, Severens JL, Schouten JS. Ocular hypertension and the risk of blindness. J Glaucoma. March 20, 2013. [Epub ahead of print.]
5. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol. 1977;95(8):1378-1382.
6. Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol. 1985;Suppl 28: 55-63.
7. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary openangle glaucoma. Arch Ophthalmol. 2002;120(6):701-713.
8. Cheng JW, Cheng SW, Gao LD, Lu GC, Wei RL. Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One. 2012;7(9):e45079.
9. Martinez A, Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther. 2009;25(3): 239-248.
10. Michaud JE, Friren B; International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235-243.
11. Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000; 44 Suppl 2:S163-S168.
12. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol. 2000;129(2):136-143.
13. Schenker H, Maloney S, Liss C, Gormley G, Hartenbaum D. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin Ther. 1999;21(1):138-147.
14. Shedden A, Laurence J, Tipping R; Timoptic-XE 0.5% Study Group. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with openangle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study. Clin Ther. 2001;23(3):440-450.
15. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63(3):333-338.
16. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18(3):238-243.
17. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B. Patientreported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113(3):431-436.
18. Auger GA, Raynor M, Longstaff S. Patient perspectives when switching from Cosopt® (dorzolamide-timolol) to Azarga (brinzolamide-timolol) for glaucoma requiring multiple drug therapy. Clin Ophthalmol. 2012;6: 2059-2062.
19. Lanzl I, Raber T. Efficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practice. Clin Ophthalmol. 2011;5:291-298.
20. Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293-300.
21. Mundorf TK, Rauchman SH, Williams RD, Notivol R; Brinzolamide/ Timolol Preference Study Group. A patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with openangle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2(3): 623-628.
22. Kaback M, Scoper SV, Arzeno G, et al; Brinzolamide 1%/Timolol 0.5% Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115(10):1728-1734.
23. Greve EL. Performance of computer assisted perimeters. Doc Ophthalmol. 1982;53(4):343-380.
24. McCarty CA, Mukesh BN, Kitchner TE, et al. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project. J Glaucoma. 2008;17(5): 372-377.
25. Kashiwagi K. Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community. Open Ophthalmol J. 2010;4:7-11.
26. Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I; Ganfort Investigators Group II. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17(3):211-216.
27. Higginbotham EJ, Olander KW, Kim EE, Grunden JW, Kwok KK, Tressler CS; United States Fixed-Combination Study Group. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol. 2010;128(2):165-172.
28. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124(9): 1230-1238.
29. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-423.
30. Sall K. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group. Surv Ophthalmol. 2000;44 Suppl 2:S155-S162.
31. Sanseau A, Sampaolesi J, Suzuki ER Jr, Lopes JF, Borel H. Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:357-362.
32. Diestelhorst M, Larsson LI; European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113(1):70-76.
33. Choudhri S, Wand M, Shields MB. A comparison of dorzolamidetimolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130(6):832-833.
34. Zhao JL, Ge J, Li XX, et al; Xalacom Study Group in China. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011;11:23.
35. Inoue K, Shiokawa M, Sugahara M, Wakakura M, Soeda S, Tomita G. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn J Ophthalmol. 2012;56(6):559-563.
36. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group. Surv Ophthalmol. 2000;44 Suppl 2:S141-S145.
37. Stein JD, Kim DS, Niziol LM, et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011;118(6):1031-1037.